Mammalian target of rapamycin: A new target in prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 2, 2010, Pages 134-138

  Rai, Jaskarn S ^a   Henley, Michael J ^a   Ratan, Hari L ^a  

^a DERBY CITY GENERAL HOSPITAL   (United Kingdom)

Author keywords

mTOR; Prostate cancer; Rapamycin

Indexed keywords

BICALUTAMIDE; DEFOROLIMUS; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; TEMSIROLIMUS;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 77249092487     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.03.023     Document Type: Review

References (39)

1. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib vs. interferon-α in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
2. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
3. Gingras A.C., Raught B., and Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 15 (2001) 807-826
4. Brown E.J., Albers M.W., Shin T.B., et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369 (1994) 756-758
5. Abraham R.T., and Wiederrecht G.J. Immunopharmacology of rapamycin. Annu Rev Immunol 14 (1996) 483-510
6. Tee R., Fingar D.C., Manning B.D., et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 99 (2002) 13571-13576
7. Inoki K., Li Y., Zhu T., et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol 4 (2002) 648-657
8. Abraham T. Identification of TOR signaling complexes: More TORC for the cell growth engine. Cell 111 (2002) 9-12
9. Ayala G., Thompson T., Yang G., et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10 (2004) 6572-6578
10. Kreisberg J.I., Malik S.N., Prihoda T.J., et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64 (2004) 5232-5236
11. Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22 (2004) 2954-2963
12. Vazquez F., and Sellers W.R. The PTEN tumor suppressor protein: An antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 1470 (2000) M21-M35
13. Sarbassov D.D., Ali S.M., Kim D.H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14 (2004) 1296-1302
14. Sarbassov D.D., Guertin D.A., Ali S.M., et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
15. Shweiki D., Itin A., Soffer D., et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359 (1992) 843-845
16. Lang K.J., Kappel A., and Goodall G.J. Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol Biol Cell 13 (2002) 1792-1801
17. Land S.C., and Tee A.R. Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 282 (2007) 20534-20543
18. Morice W.G., Brunn G.J., Wiederrecht G., et al. Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes. J Biol Chem 268 (1993) 3734-3738
19. Chan S. Targeting the mammalian target of rapamycin (mTOR): A new approach to treating cancer. Br J Cancer 91 (2004) 1420-1424
20. Barbet N.C., Schneider U., Helliwell S.B., et al. TOR controls translation initiation and early G1 progression in yeast. Mol Biol Cell 7 (1996) 25-42
21. Martel C.L., Gumerlock P.H., Meyers F.J., et al. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 29 (2003) 171-187
22. Kulik G., and Weber M.J. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol 18 (1998) 6711-6718
23. Kremer C.L., Klein R.R., Mendelson J., et al. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66 (2006) 1203-1212
24. Kim J.E., and Chen J. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc Natl Acad Sci USA 97 (2000) 14340-14345
25. Figlin R.A., Brown E., Armstrong A.J., et al. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Comprehensive Cancer Network 6 Suppl 5 (2008) S1-S20
26. Wu L., Birle D.C., and Tannock I.F. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 65 (2005) 2825-2831
27. Wang Y., Mikhailova M., Bose S., et al. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 27 (2008) 7106-7117
28. Gao H., Outang X., Banach-Petrosky W.A., et al. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci USA 103 (2006) 14477-14482
29. Gao N., Zhang Z., Jiang B.H., et al. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 310 (2003) 1124-1132
30. Danielpour D. Functions and regulation of transforming growth factor-beta (TGF-β) in the prostate. Eur J Cancer 41 (2005) 846-857
31. Itoh S., Jtoh F., Goumans M.J., et al. Signaling of transforming growth factor-β family members through SMAD proteins. Eur J Biochem 267 (2000) 6954-6967
32. Blobe G.C., Schiemann W.P., and Lodish H.F. Role of transforming growth factor-β in human disease. N Engl J Med 342 (2000) 1350-1358
33. Fynan T.M., and Reiss M. Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit Rev Oncog 4 (1993) 493-540
34. Markowitz S.D., and Roberts A.B. Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev 7 (1996) 93-102
35. van der Poel H.G., Hanrahan C., Zhong H., et al. Rapamycin induces Smad activity in prostate cancer cell lines. Urol Res 30 (2003) 380-386
36. van der Poel H.G. Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-β1 in prostate cancer cells. J Urol 172 4 Pt 1 (2004) 1333-1337
37. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
38. Motzer R.J., Hudes G.R., Curti B.D., et al. Phase I/II trial of temsirolimus combined with interferon α for advanced renal cell carcinoma. J Clin Oncol 25 (2007) 3958-3964
39. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918